Genomic Health (GHDX) Shines on Prospective Cancer Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 4:50PM CST
Genomic Health (GHDX) strongly believes that its Oncotype DX prostate cancer test will strengthen its advanced next generation sequencing (NGS) platform and accelerate the development of future tests.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), AFFX: 9.80 (+0.05), GHDX: 32.44 (+1.32)
Claritas Genomics Appoints Patrick F. Terry as Chief Commercial Officer
PR Newswire - Thu Dec 18, 7:00AM CST
Claritas Genomics today announced the appointment of Patrick F. Terry to the role of Chief Commercial Officer. Mr. Terry, Chairman, Gray Group Ventures Ltd., and a founder of Genomic Health, Inc. [NASDAQ: GHDX], has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery. Mr. Terry will build Claritas's commercial organization to expand the company's reach to pediatric hospitals and patients and ensure that the Claritas services also meet the needs of payers. He will report to Claritas's President and Chief Executive Officer Patrice Milos, Ph.D.
GHDX: 32.44 (+1.32)
Genomic Health's Oncotype DX Positive in Multiple Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 3:50PM CST
Developer of genomic-based clinical laboratory services, Genomic Health Inc. (GHDX) recently announced positive feedback from the clinical validation study of Oncotype DX in patients with a pre-invasive form of breast cancer known as DCIS.
MYGN: 36.50 (+0.28), HOLX: 26.89 (+0.10), GHDX: 32.44 (+1.32), NVS: 93.91 (+0.66)
Genomic Health's Breast Cancer Test Yields Positive Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 1:30PM CST
Oncotype DX breast cancer test ??? as Genomic Health's (GHDX) first product ??? has been an important contributor to U.S. invasive breast cancer business revenues since its launch in 2004.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), GHDX: 32.44 (+1.32), AFFX: 9.80 (+0.05)
United States Medical Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lncwzs/medical) has announced the addition of Plunkett Research Ltd's new report "Medical Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical Laboratories Industry (U.S.) to reach $218.2 billion by 2021. - Medical Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - Medytox Solutions Inc - NeoGenomics Inc - Psychemedics Corporation - Quest Diagnostics Inc For more information visit http://www.researchandmarkets.com/research/lncwzs/medical Source: Plunkett Research Ltd
PMD: 14.90 (+0.05), HH: 0.53 (unch), BRLI: 31.82 (+0.55), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)
United States Medical and Diagnostic Laboratories Industry Analytics 2014-2021 - Extensive Financial Benchmarks, Metrics and Revenue Forecasts
M2 - Mon Dec 15, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/k6lcqc/medical_and) has announced the addition of Plunkett Research Ltd's new report "Medical and Diagnostic Laboratories Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Key Findings: - Medical and Diagnostic Laboratories Industry (U.S.) to reach $80.8 billion by 2021. - Medical and Diagnostic Laboratories Industry, including Average EBITDA, Operating Ratios and Sales per Employee. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital Comparison of Individual Top Publicly-Held Companies to Industry Averages, 2013 - Income Statements. Balance Sheets and Cash Flow Statements Companies Mentioned - Alliance Healthcare Services Inc - AmeriPath Inc - Bio-Reference Laboratories Inc - Genomic Health Inc - Hooper Holmes Inc - Laboratory Corp of America Holdings - MEDTOX Scientific Inc - NeoGenomics Inc - Quest Diagnostics Inc - RadNet Inc For more information visit http://www.researchandmarkets.com/research/k6...edical_and Source: Plunkett Research Ltd
HH: 0.53 (unch), BRLI: 31.82 (+0.55), RDNT: 9.41 (-0.08), NEO: 4.03 (-0.10), DGX: 67.94 (-0.16), LH: 107.69 (+0.56), GHDX: 32.44 (+1.32)
Genomic Health: New Oncotype DX(R) Data Presented at 2014 San Antonio Breast Cancer Symposium Further Demonstrate the Practice-Changing Impact of the Test in Guiding the Treatment of Early Stage Breast Cancer
Business Wire - Mon Dec 15, 1:00AM CST
--Positive results of second large, independent validation study in DCIS breast cancer
GHDX: 32.44 (+1.32)
Oncotype DX® DCIS Score(TM) Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer
PR Newswire - Fri Dec 12, 7:30AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from the second large clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group of Sunnybrook Health Sciences Centre in Canada, reconfirmed that the Oncotype DX DCIS Score(TM) is a strong predictor of local recurrence, which could be either invasive breast cancer or DCIS (p<0.001).
GHDX: 32.44 (+1.32)
Genomic Health's Liquid Biopsy Tests Positive in Twin Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:40PM CST
Genomic Health (GHDX) is conducting larger-scale proof-of-concept studies investigating analytical methods that will use liquid biopsy samples for accurate and scalable genomic analysis in breast and bladder cancer patients.
BIIB: 340.89 (+5.13), ANIP: 55.24 (+1.79), GHDX: 32.44 (+1.32), AFFX: 9.80 (+0.05)
Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test
PR Newswire - Wed Dec 10, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced early results from Europe's largest contemporary adjuvant breast cancer trial, which used the Oncotype DX® breast cancer test to identify higher-risk patients who would benefit from the treatment. The early results of the study, conducted by the Women's Healthcare Study Group (WSG), represent the first prospective outcomes data on prognosis supporting the use of Oncotype DX to guide whether to add chemotherapy to standard hormonal therapy in estrogen receptor positive breast cancer.
GHDX: 32.44 (+1.32)
Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests
PR Newswire - Tue Dec 09, 8:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from its first two feasibility studies assessing multiple technologies, including next-generation sequencing, for their ability to detect and characterize the presence of bladder cancer DNA in urine and breast cancer DNA in blood.
GHDX: 32.44 (+1.32)
Genomic Health's Oncotype DX: Cancer Testing Made Easier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 1:40PM CST
In association with upgraded tools like genomic profiling, Genomic Health's Oncotype DX can diagnose an individual patient's risk accurately
MYGN: 36.50 (+0.28), ANIP: 55.24 (+1.79), GHDX: 32.44 (+1.32), AFFX: 9.80 (+0.05)
Genomic Health (GHDX) Downgraded From Hold to Sell
at The Street - Wed Dec 03, 8:21AM CST
Genomic Health (GHDX) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D+.
GHDX: 32.44 (+1.32)
Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations
PR Newswire - Wed Dec 03, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two studies of the Oncotype DX® prostate cancer test demonstrating its value in low- and intermediate-risk prostate cancer to enable physicians and patients to avoid over- and under-treatment of the disease. Both studies will be presented today, December 3, at the Society of Urologic Oncology (SUO) Annual Meeting, in Bethesda, Md.
GHDX: 32.44 (+1.32)
2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12
PR Newswire - Tue Dec 02, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that positive results from the second large, independent clinical validation study of Oncotype DX® in patients with DCIS (ductal carcinoma in situ) breast cancer will be featured in the press program of the 37th Annual San Antonio Breast Cancer Symposium (SABCS) on December 12 at 7:30 a.m. Central Time (CT) in room 217D of the Henry B. Gonzales Convention Center.
GHDX: 32.44 (+1.32)
Genomic Health to participate at the 26th Annual Piper Jaffray Healthcare Conference
M2 - Fri Nov 28, 3:00AM CST
Genomic Health (Nasdaq:GHDX) revealed on Thursday that Kim Popovits, chairman, chief executive officer and president, will take part in the 26th Annual Piper Jaffray Healthcare Conference in New York on 3 December at 11:30 Eastern Time (ET).
GHDX: 32.44 (+1.32)
Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Wed Nov 26, 3:00PM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Chairman, Chief Executive Officer and President, will participate in the 26th Annual Piper Jaffray Healthcare Conference at The New York Palace Hotel in New York on Wednesday, December 3 at 11:30 am Eastern Time (ET).
GHDX: 32.44 (+1.32)
Diagnostics Marketing Association Accepting Nominations for 2014 Marketer of the Year Award
PRWeb - Tue Nov 25, 2:27AM CST
The DxMA is proud to announce that they will once again be awarding the Marketer of the Year Award. The Marketer of the Year Award is the highest accolade the DxMA offers for diagnostics companies, recognizing outstanding work that raises the bar in diagnostics marketing. Genomic Health was awarded the 2013 Marketer of the Year Award for their "Pass It On, Until Every Woman Know" Campaign.
GHDX: 32.44 (+1.32)
Post Earnings Update: Genomic Health Has Sunk 5.7% Lower in Past 2 Weeks (GHDX)
Comtex SmarTrend(R) - Mon Nov 24, 9:44AM CST
When Genomic Health (NASDAQ:GHDX) reported earnings two weeks ago on November 4th, 2014, analysts, on average, expected the company to report a loss of $0.22 on sales of $71.1 million. The company actually reported a loss of $0.20 per share on sales of $69.1 million, beating EPS estimates by $0.02 and missing revenue estimates by $2.0 million. Shares of Genomic Health have slipped from $35.19 to $33.17, representing a loss of 5.7%, since the company reported earnings 20 days ago.
GHDX: 32.44 (+1.32)
Results from Second Oncotype DX® Prostate Cancer Test Clinical Validation and First Decision Impact Study To Be Published in European Urology and Urology Practice, Respectively
PR Newswire - Wed Nov 19, 7:00AM CST
Genomic Health, Inc. (Nasdaq: GHDX) today announced multiple upcoming presentations at the 2014 Society of Urologic Oncology (SUO) Annual Meeting, including the second large, independent clinical validation study of the Oncotype DX® prostate cancer test and results from the first prostate cancer decision impact study.
GHDX: 32.44 (+1.32)